US 2021/0330625 A1Published application

Lipid formulations containing bioactive fatty acids

AssigneeSciadonics, Inc.

InventorAlvin Berger

Life of this patent

Estimating the term…

Abstract

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions containing defined ratios of 5,11,14-eicosatrienoic acid to one or more of: 5, 9, 12-octadecatrienoic acid; 7, 11, 14-eicosatrienoic acid; 5, 8, 11, 14-eicosatetraenoic acid; 9, 12-octadecadienoic acid; 9-octadecenoic acid; 14-methylhexadecanoic acid; 11, 14 eicosadienoic acid, 5, 9-octadecadienoic acid; 5, 11-octadecadienoic acid; 9, 12, 15-octadecatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid; 7,10,13,16,19-docosapentaenoic acid; and 4,7,10,13,16,19-docosahexaenoic acid.

Claims20

Dependent claims

A lipid formulation comprising an effective amount of 5,11,14-eicosatrienoic acid, wherein said lipid formulation is suitable for human consumption and one or more of the following properties:

a) the formulation comprises 5, 9, 12-octadecatrienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 9, 12-octadecatrienoic acid is selected from the group consisting of 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1, 1.5:1 to 2.5:1, 1.8:1 to 2.2:1, 1:2 to 1:20, 1:2 to 1:10, and 1:2 to 1:7;
b) the formulation comprises 7, 11, 14-eicosatrienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
7, 11, 14-eicosatrienoic acid is selected from the group consisting of 3.5:1 to 6.5:1, 4:1 to 6:1, and 4.5:1 to 5.5:1;
c) the formulation comprises at least trace amounts of an acid selected from the group consisting of abietic acid, pimaric acid and 5, 9, 12, 15-octadecatetraenoic acid, in combination with 5,11,14-eicosatrienoic acid,
d) the formulation comprises 5, 8, 11, 14-eicosatetraenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 8, 11, 14-eicosatetraenoic acid is selected from the group consisting of 1:1 to 25:1, 3:1 to 25:1, 10:1 to 25:1, 1:1 to 10:1, and 3:1 to 10:1;
e) the formulation comprises 14-methylhexadecanoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
14-methylhexadecanoic acid is selected from the group consisting of 1:1 to 25:1, 1:1 to 10:1, 2:1 to 8:1, 3:1 to 7:1 and 4:1 to 6:1;
f) the formulation comprises 9, 12-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
9, 12-octadecadienoic acid is selected from the group consisting of 1:1 to 25:1, 2:1 to 25:1, 5:1 to 25:1, 10:1 to 25:1, 1:1 to 20:1, 2:1 to 20:1, 5:1 to 20:1, 10:1 to 20:1, 1:1 to 10:1, 2:1 to 10:1, 5:1 to 10:1, 1:1 to 1:25, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3 and 1:1 to 2.5:1;
g) the formulation comprises 9-octadecenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
9, 12-octadecadienoic acid is selected from the group consisting of 1:1 to 25:1, 2:1 to 25:1, 5:1 to 25:1, 10:1 to 25:1, 1:1 to 20:1, 2:1 to 20:1, 5:1 to 20:1, 10:1 to 20:1, 1:1 to 10:1, 2:1 to 10:1, 5:1 to 10:1, 1:5 to 5:1, 1:4 to 4:1, 1:3 to 3:1, 1:2 to 2:1, and 1:1.5 to 1.5:1;
h) the formulation comprises 5, 9-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 9-octadecadienoic acid is selected from the group consisting of 1:1 to 1:10, 1:2 to 1:8, 1:3 to 1:7, and 1:4 to 1:6;
i) the formulation comprises 5, 11-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 11-octadecadienoic acid is selected from the group consisting of 1:1 to 10:1, 1:1 to 5:1, 1:1 to 4:1, 1:1 to 3:1, 1:1 to 1:2:1, 1:2 to 5:1, and 1:2 to 1:4;
j) the formulation comprises 5,8,11,14,17-eicosapentaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5,8,11,14,17-eicosapentaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;
k) the formulation comprises 4,7,10,13,16,19-docosahexaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
4,7,10,13,16,19-docosahexaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;
l) the formulation comprises 7,10,13,16,19-docosapentaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
7,10,13,16,19-docosapentaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;
m) the formulation comprises 11, 14 eicosadienoic acid (20:2 n-6), wherein the ratio of 5, 11,14-eicosatrienoic acid to 11, 14 eicosadienoic acid (20:2 n-6) is selected from the group consisting of from 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1 , 1:1 to 2.5:1, 1.5:
1 to 5:1, 1.5:1 to 3:1, 1.5:1 to 2.5:1, and 1.5:1 to 2:1;
and
n) the formulation comprises gammalinolenic acid (6, 9, 12 18:3) and/or dihommogammalinolenic acid (8,11,14 20:3), wherein the ratio of 5,11,14-eicosatrienoic acid to gammalinolenic acid (6, 9, 12 18:3) and/or dihommogammalinolenic acid (8,11,14 20:3) is selected from the group consisting of from 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1 , 1:1 to 2.5:1, 1.5:
1 to 5:1, 1.5:1 to 3:1, 1.5:1 to 2.5:1, and 1.5:1 to 2:1.

25 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/369,568Filed 7 Jul 2021
Priority: 25 Nov 2015
Published: 28 Oct 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/202
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: having three or more double…
A23L 33/12
Fatty acids or derivatives thereof; Fats or oils: fatty acids or derivatives thereof
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A23V 2002/00
Food compositions, function of food ingredients or processes for food or foodstuffs

Family

Application62/259,785Us provisional application · filed 25 Nov 2015
Application62/303,170Us provisional application · filed 3 Mar 2016
Application62/363,425Us provisional application · filed 18 Jul 2016
Application15/778,969Continuation · filed 24 May 2018
Application17/369,568Continuation
US 11,058,656 B2Related patent
US 2018/0353453 A1Published application
US 2021/0330625 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

A lipid formulation comprising an effective amount of 5,11,14-eicosatrienoic acid, wherein said lipid formulation is suitable for human consumption and one or more of the following properties:

a) the formulation comprises 5, 9, 12-octadecatrienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 9, 12-octadecatrienoic acid is selected from the group consisting of 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1, 1.5:1 to 2.5:1, 1.8:1 to 2.2:1, 1:2 to 1:20, 1:2 to 1:10, and 1:2 to 1:7;
b) the formulation comprises 7, 11, 14-eicosatrienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
7, 11, 14-eicosatrienoic acid is selected from the group consisting of 3.5:1 to 6.5:1, 4:1 to 6:1, and 4.5:1 to 5.5:1;
c) the formulation comprises at least trace amounts of an acid selected from the group consisting of abietic acid, pimaric acid and 5, 9, 12, 15-octadecatetraenoic acid, in combination with 5,11,14-eicosatrienoic acid,
d) the formulation comprises 5, 8, 11, 14-eicosatetraenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 8, 11, 14-eicosatetraenoic acid is selected from the group consisting of 1:1 to 25:1, 3:1 to 25:1, 10:1 to 25:1, 1:1 to 10:1, and 3:1 to 10:1;
e) the formulation comprises 14-methylhexadecanoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
14-methylhexadecanoic acid is selected from the group consisting of 1:1 to 25:1, 1:1 to 10:1, 2:1 to 8:1, 3:1 to 7:1 and 4:1 to 6:1;
f) the formulation comprises 9, 12-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
9, 12-octadecadienoic acid is selected from the group consisting of 1:1 to 25:1, 2:1 to 25:1, 5:1 to 25:1, 10:1 to 25:1, 1:1 to 20:1, 2:1 to 20:1, 5:1 to 20:1, 10:1 to 20:1, 1:1 to 10:1, 2:1 to 10:1, 5:1 to 10:1, 1:1 to 1:25, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3 and 1:1 to 2.5:1;
g) the formulation comprises 9-octadecenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
9, 12-octadecadienoic acid is selected from the group consisting of 1:1 to 25:1, 2:1 to 25:1, 5:1 to 25:1, 10:1 to 25:1, 1:1 to 20:1, 2:1 to 20:1, 5:1 to 20:1, 10:1 to 20:1, 1:1 to 10:1, 2:1 to 10:1, 5:1 to 10:1, 1:5 to 5:1, 1:4 to 4:1, 1:3 to 3:1, 1:2 to 2:1, and 1:1.5 to 1.5:1;
h) the formulation comprises 5, 9-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 9-octadecadienoic acid is selected from the group consisting of 1:1 to 1:10, 1:2 to 1:8, 1:3 to 1:7, and 1:4 to 1:6;
i) the formulation comprises 5, 11-octadecadienoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5, 11-octadecadienoic acid is selected from the group consisting of 1:1 to 10:1, 1:1 to 5:1, 1:1 to 4:1, 1:1 to 3:1, 1:1 to 1:2:1, 1:2 to 5:1, and 1:2 to 1:4;
j) the formulation comprises 5,8,11,14,17-eicosapentaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
5,8,11,14,17-eicosapentaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;
k) the formulation comprises 4,7,10,13,16,19-docosahexaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
4,7,10,13,16,19-docosahexaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;
l) the formulation comprises 7,10,13,16,19-docosapentaenoic acid, wherein the ratio of 5,11,14-eicosatrienoic acid:
7,10,13,16,19-docosapentaenoic acid is selected from the group consisting of 20:1 to 1:20, 10:1 to 1:10, 5:1 to 1:5, 3:1 to 1:3, 1:1 to 1:20, 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:3, 20:1 to 1:1, 10:1 to 1:1, 5:1 to 1:1, and 3:1 to 1:1;
m) the formulation comprises 11, 14 eicosadienoic acid (20:2 n-6), wherein the ratio of 5, 11,14-eicosatrienoic acid to 11, 14 eicosadienoic acid (20:2 n-6) is selected from the group consisting of from 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1 , 1:1 to 2.5:1, 1.5:
1 to 5:1, 1.5:1 to 3:1, 1.5:1 to 2.5:1, and 1.5:1 to 2:1;
and
n) the formulation comprises gammalinolenic acid (6, 9, 12 18:3) and/or dihommogammalinolenic acid (8,11,14 20:3), wherein the ratio of 5,11,14-eicosatrienoic acid to gammalinolenic acid (6, 9, 12 18:3) and/or dihommogammalinolenic acid (8,11,14 20:3) is selected from the group consisting of from 1:1 to 10:1, 1:1 to 5:1, 1:1 to 3:1 , 1:1 to 2.5:1, 1.5:
1 to 5:1, 1.5:1 to 3:1, 1.5:1 to 2.5:1, and 1.5:1 to 2:1.

25 more elements

Facts

Application

17/369,568Filed 7 Jul 2021

Priority

25 Nov 2015

Published

28 Oct 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/202
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: having three or more double…
A23L 33/12
Fatty acids or derivatives thereof; Fats or oils: fatty acids or derivatives thereof
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A23V 2002/00
Food compositions, function of food ingredients or processes for food or foodstuffs

Family

Application62/259,785Us provisional application · filed 25 Nov 2015

Application62/303,170Us provisional application · filed 3 Mar 2016

Application62/363,425Us provisional application · filed 18 Jul 2016

Application15/778,969Continuation · filed 24 May 2018

Application17/369,568Continuation

US 11,058,656 B2Related patent

US 2018/0353453 A1Published application

US 2021/0330625 A1This patent

From the US filing history. Foreign family members aren’t listed.